DeutschNewstral
Article
Mmarketwatch.com on 2017-06-23 20:08
Portola Pharma stock skyrockets after FDA approves anticoagulant for high-risk patients
Related news
- MPortola Pharma stock falls 7% after delay in FDA reviewmarketwatch.com
FDA approves new option for cancer patientsCNN- MAdamis Pharma stock skyrockets after rival EpiPen product gets FDA approvalmarketwatch.com
FDA approves 1st dissolving stent for US patientstheledger.com
FDA approves system to warn doctors before coronavirus patients deteriorateNew York Post
FDA approves first dissolving stent for US patientswaff.com- FDA approves third vaccination shot for at-risk patientsNew York Post
FDA approves Amgen cholesterol-lowering drug Repatha for some patientsLA Times
FDA approves female sexual desire drug made by Raleigh's Sprout Pharmabizjournals.com
FDA approves TB pill that cures more hard-to treat patients - Wed, 14 Aug 2019 PSTThe Spokesman-Review
FDA protects Big Pharmakentucky.com- FDA approves injectable testosterone drug patients can administer by themselves at homebizjournals.com
FDA approves first-ever pill that can be tracked by patients and doctors when swallowedUSA today- FDA approves Lucemyra to treat symptoms of opioid withdrawal and help patients overcome addictionLA Times
- FDA approves cholesterol drug for high-risk patients - Sat, 25 Jul 2015 PSTThe Spokesman-Review
FDA approves generic EpiPenArkansas Online- TFDA Approves Comirnaty Vaccinethedmonline.com
FDA approves leukemia drugThe Toledo Blade
FDA Approves Migraine Medicinewsj.com